专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20220202901A1 PEPTIDES IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR USE IN TREATMENT OF CANCER 有权
公开(公告)号：US20220202901A1
公开(公告)日：2022-06-30
申请号：US17604356
申请日：2020-04-16
申请人： WNTRESEARCH AB
发明人： Peter Johannes HOLST , Lena AXELSSON , Tommy ANDERSSON
IPC分类号： A61K38/18 , A61K39/395 , A61P35/00
摘要： A WNT5A peptide or derivatives thereof in combination with one or more checkpoint inhibitors for use in treatment of cancer in a subject in need thereof. Furthermore, WNT5A peptides or derivatives thereof may be used in treatment of cancer in a subject, wherein the subject is responsive to immune checkpoint inhibitors.

2. 发明授权

US11912791B2 Solution phase routes for Wnt hexapeptides 有权
公开(公告)号：US11912791B2
公开(公告)日：2024-02-27
申请号：US17267764
申请日：2019-08-19
申请人： WNTRESEARCH AB
发明人： Dennis Henriksen
IPC分类号： C07K7/06 , C07K5/083
CPC分类号： C07K7/06 , C07K5/081
摘要： The present disclosure relates generally to the field of polypeptide synthesis, and more particularly, to the solution phase synthesis of the Wnt hexapeptide Foxy-5 and protected derivatives and peptide fragments thereof.

3. 发明公开

US20230295232A1 SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES 审中-公开
公开(公告)号：US20230295232A1
公开(公告)日：2023-09-21
申请号：US18184605
申请日：2023-03-15
申请人： WNTRESEARCH AB
发明人： Dennis HENRIKSEN
IPC分类号： C07K7/06 , C07K5/083
CPC分类号： C07K7/06 , C07K5/081
摘要： The present disclosure relates generally to the field of polypeptide synthesis, and more particularly, to the solution phase synthesis of the Wnt hexapeptide Foxy-5 and protected derivatives and peptide fragments thereof.

4. 发明授权

US09278119B2 Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients 有权
标题翻译：前列腺癌的治疗和前列腺癌患者预后的确定方法
公开(公告)号：US09278119B2
公开(公告)日：2016-03-08
申请号：US14128064
申请日：2012-06-28
申请人： Tommy Andersson , Anders Bjartell
发明人： Tommy Andersson , Anders Bjartell
IPC分类号： A61K38/04 , C07K7/00 , A61P35/00 , A61K38/10 , C07K14/475 , G01N33/50 , G01N33/574 , A61K38/08
CPC分类号： A61K38/10 , A61K38/08 , C07K14/475 , G01N33/5088 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis.
摘要翻译：本发明涉及具有Wnt5a信号传导特性的Wnt5a蛋白或其肽，例如Foxy5，用于治疗前列腺癌，特别是在经历或将进行根治性前列腺切除术的患者中。本发明还涉及一种用于确定具有前列腺癌的患者的预后的方法和用于执行所述方法的试剂盒。用于确定患者预后的方法包括以下步骤：评估存在于患者早期获得的样品的至少部分中的Wnt5a蛋白质的量并确定与所述评估量相对应的样品值; 将步骤a）中获得的样品值与参考预后相关的参考值进行比较; 并且如果所述样品值高于所述参考值，则认为所述患者的预后优于所述参考预后。

5. 发明授权

US12129277B2 Linear solution phase routes for WNT hexapeptides 有权
公开(公告)号：US12129277B2
公开(公告)日：2024-10-29
申请号：US17299745
申请日：2019-12-02
申请人： WNTRESEARCH AB
发明人： Tadikonda Veerabhadra Pratap , Kamaraju Raghavendra Rao , Dennis Henriksen
IPC分类号： C07K1/06 , C07K14/475
CPC分类号： C07K1/063 , C07K14/475
摘要： The present disclosure relates generally to the field of polypeptide synthesis, and more particularly, to a linear solution phase synthesis of the Wnt hexapeptide Foxy-5 and protected derivatives and peptide fragments thereof.

6. 发明公开

US20240226234A1 WNT5A PEPTIDES FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA 审中-公开
公开(公告)号：US20240226234A1
公开(公告)日：2024-07-11
申请号：US18562783
申请日：2022-05-03
申请人： WNTRESEARCH AB
发明人： Sara Teresinha SAAD , Fernanda Marconi ROVERSI , Maura Lima Pereira BUENO
IPC分类号： A61K38/17 , A61K45/06 , A61P35/02
CPC分类号： A61K38/1709 , A61K45/06 , A61P35/02
摘要： A WNT5A peptide or derivatives thereof for use in treatment of acute myelogenous leukemia in a subject in need thereof. Further, the WNT5A peptide or derivatives thereof may be in combination with at least one chemotherapeutic drug or blood transfusion for use in treatment of acute myelogenous leukemia in a subject in need thereof.

7. 发明申请

US20140206623A1 TREATMENT OF PROSTATE CANCER AND A METHOD FOR DETERMINING THE PROGNOSIS FOR PROSTATE CANCER PATIENTS 有权
标题翻译：前列腺癌的治疗方法及确定前列腺癌患者预后的方法
公开(公告)号：US20140206623A1
公开(公告)日：2014-07-24
申请号：US14128064
申请日：2012-06-28
申请人： Tommy Andersson , Anders Bjartell
发明人： Tommy Andersson , Anders Bjartell
IPC分类号： A61K38/10 , G01N33/574 , A61K38/08
CPC分类号： A61K38/10 , A61K38/08 , C07K14/475 , G01N33/5088 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to a Wnt5a protein or peptide thereof possessing Wnt5a signaling properties, such as Foxy5, for use in the treatment of prostate cancer, in particular in patients that have undergone or will undergo radical prosteatectomy. The invention also relates to a method for determining a prognosis for a patient having prostate cancer and a kit for performing said method. The method for determining a prognosis for a patient comprises the steps of: evaluating an amount of Wnt5a protein present in at least part of a sample earlier obtained from the patient and determining a sample value corresponding to the evaluated amount; comparing the sample value obtained in step a) with a reference value associated with a reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said patient is better than said reference prognosis.
摘要翻译：本发明涉及具有Wnt5a信号传导特性的Wnt5a蛋白或其肽，例如Foxy5，用于治疗前列腺癌，特别是在经历或将进行根治性前列腺切除术的患者中。本发明还涉及一种用于确定具有前列腺癌的患者的预后的方法和用于执行所述方法的试剂盒。用于确定患者预后的方法包括以下步骤：评估存在于患者早期获得的样品的至少部分中的Wnt5a蛋白质的量并确定与所述评估量相对应的样品值; 将步骤a）中获得的样品值与参考预后相关的参考值进行比较; 并且如果所述样品值高于所述参考值，则认为所述患者的预后优于所述参考预后。

8. 发明授权

US08674060B2 Peptide ligand to impair cancer cell migration 有权
标题翻译：肽配体损害癌细胞迁移
公开(公告)号：US08674060B2
公开(公告)日：2014-03-18
申请号：US11946303
申请日：2007-11-28
申请人： Tommy Andersson
发明人： Tommy Andersson
IPC分类号： C07K7/04 , C07K7/06 , C07K7/08 , A61K38/08 , A61K38/10
CPC分类号： C07K14/475 , A61K38/00
摘要： Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a, peptide fragments were identified and investigated for their ability to mimic effects of the Wnt-5a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumorigenic breast cancer cell lines, both low in endogenous Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumor cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectable. However, formulation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumor cell motility. The formyl-Met-Asp-Gly-Cys-Glu-Leu (formylated SEQ ID NO: 15) peptide ligand can serve as a lead substance for anti-metastatic treatment in the 50% of human breast cancers where the endogenous expression of Wnt-5a is reduced.
摘要翻译：乳腺癌患者Wnt-5a蛋白表达的丧失与乳腺细胞系的无复发生存期以及运动能力增加有关。基于Wnt-5a的序列分析，鉴定并研究了肽片段模拟Wnt-5a蛋白对乳腺细胞粘附和运动性的影响的能力。这些肽中的两种显着增加了粘附性并且损害了非致瘤性乳腺癌细胞系的运动性，内源性Wnt-5a蛋白表达低。为了鉴定仍然具有抗运动作用的最短可能的肽，进行了两个氨基酸从这两个较短的肽的N末端侧的连续缺失。对肿瘤细胞粘附的影响逐渐丧失，只有6个氨基酸仍然没有检测到。然而，该六肽的N-末端甲硫氨酸的配方恢复了其对粘附的作用和降低的肿瘤细胞运动性。甲酰基-Mly-Asp-Gly-Cys-Glu-Leu（甲酰化的SEQ ID NO：15）肽配体可以作为在50％的人乳腺癌中进行抗转移治疗的铅物质，其中Wnt- 5a减少。

9. 发明授权

US11970551B2 Solution phase routes for WNT hexapeptides 有权
公开(公告)号：US11970551B2
公开(公告)日：2024-04-30
申请号：US18184605
申请日：2023-03-15
申请人： WNTRESEARCH AB
发明人： Dennis Henriksen
IPC分类号： C07K7/06 , C07K5/083
CPC分类号： C07K7/06 , C07K5/081
摘要： The present disclosure relates generally to the field of polypeptide synthesis, and more particularly, to the solution phase synthesis of the Wnt hexapeptide Foxy-5 and protected derivatives and peptide fragments thereof.

10. 发明申请

US20220017568A1 LINEAR SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES 有权
公开(公告)号：US20220017568A1
公开(公告)日：2022-01-20
申请号：US17299745
申请日：2019-12-02
申请人： WNTRESEARCH AB
发明人： Tadikonda VEERABHADRA PRATAP , Kamaraju RAGHAVENDRA RAO , Dennis HENRIKSEN
IPC分类号： C07K1/06 , C07K14/475
摘要： The present disclosure relates generally to the field of polypeptide synthesis, and more particularly, to a linear solution phase synthesis of the Wnt hexapeptide Foxy-5 and protected derivatives and peptide fragments thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式